Comparison · NCT01531959-fed0cc06
Midodrine vs Placebo: Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Midodrine vs Placebo: Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias. Trial comparisons, record NCT01531959-fed0cc06. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01531959-fed0cc06
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.182 | 0.107 | 0.291 | wilson | |
| Risk in group 2 | 0.0455 | 0.0156 | 0.125 | wilson | |
| Risk difference, group 1 minus group 2 | 0.136 | 0.027 | 0.25 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 4 | 1.18 | 13.5 | log | |
| Odds ratio, group 1 over group 2 | 4.67 | 1.25 | 17.4 | log | |
| Number needed to treat, for one more participant with the outcome on Midodrine than on Placebo | 7.33 | 4 | 37 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Midodrine | Midodrine: Patients will be randomized to blinded to 20 mg of midodrine | 12 | 66 | OG000 |
| Group 2 | Placebo | Placebo: Patients will be randomized to blinded placebo control | 3 | 66 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias
- Description
Measured rates of hypertension (increase in systolic blood pressure to values higher than those set by the primary team or greater than 160 mmg), bradycardia (decrease in heart rate to values lower than those set by the primary team or less than 40 BPM), hemodynamically significant tachyarrythmias (greater than 20 mmhg decrease in systolic blood pressure).
- Time frame
- From initiation of the study drug until discontinuation of the study drug, an average of 59 hours.
- Population
Source ClinicalTrials.gov
Trial
- Title
- Midodrine for the Treatment of Refractory Hypotension
- NCT number
- NCT01531959
- Phases
- PHASE3
- Conditions
- Hypotension, Critical Illness
- Interventions
- Midodrine, Placebo
- Lead sponsor
- Massachusetts General Hospital
- Results first posted
- 2019-09-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01531959?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01531959-fed0cc06